Author:
Nitzahn Matthew,Allegri Gabriella,Khoja Suhail,Truong Brian,Makris Georgios,Häberle Johannes,Lipshutz Gerald S.
Funder
National Institutes of Health
Subject
Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine
Reference50 articles.
1. A major polypeptide component of rat liver mitochondria: carbamyl phosphate synthetase;Clarke;J. Biol. Chem.,1976
2. Sources and Fates of Carbamyl Phosphate: A Labile Energy-Rich Molecule with Multiple Facets;Shi;Biology (Basel),2018
3. Summar, M.L., Koelker, S., Freedenberg, D., Le Mons, C., Haberle, J., Lee, H.S., and Kirmse, B.; European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD). Electronic address: http://www.e-imd.org/en/index.phtml; Members of the Urea Cycle Disorders Consortium (UCDC). Electronic address: http://rarediseasesnetwork.epi.usf.edu/ucdc/ (2013). The incidence of urea cycle disorders. Mol. Genet. Metab. 110, 179–180.
4. Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland;Nettesheim;Orphanet J. Rare Dis.,2017
5. Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder;Diez-Fernandez;Expert Opin. Ther. Targets,2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献